Z Squared Establishes New Advisory Board with Jon Najarian, Pete Najarian, Marc Lopresti, and Jay Zapata
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ZSQR?
Source: moomoo
New Advisory Board Formation: A new advisory board has been formed, consisting of notable figures including Jon Najarian, Pete Najarian, Marc Loprieno, and Jay Zapata.
Purpose of the Board: The advisory board aims to provide strategic guidance and insights to enhance decision-making and operational effectiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZSQR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZSQR
Wall Street analysts forecast ZSQR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 12.980
Low
Averages
High
Current: 12.980
Low
Averages
High

No data
About ZSQR
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its segments are Biotechnology and Technology. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

New Advisory Board Formation: A new advisory board has been formed, consisting of notable figures including Jon Najarian, Pete Najarian, Marc Loprieno, and Jay Zapata.
Purpose of the Board: The advisory board aims to provide strategic guidance and insights to enhance decision-making and operational effectiveness.
See More





